PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · IEX Real-Time Price · USD
3.870
+0.010 (0.26%)
At close: Jul 19, 2024, 4:00 PM
4.000
+0.130 (3.36%)
Pre-market: Jul 22, 2024, 9:00 AM EDT
PDS Biotechnology Employees
PDS Biotechnology had 25 employees as of December 31, 2023. The number of employees decreased by 1 or -3.85% compared to the previous year.
Employees
25
Change (1Y)
-1
Growth (1Y)
-3.85%
Revenue / Employee
n/a
Profits / Employee
-$1,755,430
Market Cap
141.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 25 | -1 | -3.85% |
| Dec 31, 2022 | 26 | 4 | 18.18% |
| Dec 31, 2021 | 22 | 7 | 46.67% |
| Dec 31, 2020 | 15 | 0 | - |
| Dec 31, 2019 | 15 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| InfuSystem Holdings | 516 |
| Amylyx Pharmaceuticals | 384 |
| Cellectis | 221 |
| Myomo | 106 |
| EUDA Health Holdings | 106 |
| Vigil Neuroscience | 69 |
| Elevation Oncology | 29 |
| Citius Pharmaceuticals | 22 |
PDSB News
- 2 months ago - PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer - GlobeNewsWire
- 2 months ago - PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024 - GlobeNewsWire
- 2 months ago - PDS Biotechnology Announces Details of Virtual KOL Event - GlobeNewsWire
- 2 months ago - PDS Biotech Appoints Stephan Toutain as Chief Operating Officer - GlobeNewsWire
- 3 months ago - PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer - GlobeNewsWire
- 4 months ago - PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results - GlobeNewsWire
- 4 months ago - PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results - GlobeNewsWire